CTTI Welcomes Four New Members to its Executive Committee
Today, CTTI welcomed four new members to its Executive Committee, which is responsible for making decisions about the overall direction and strategy for the organization. The new Executive Committee members, whose three-year term runs from 2022-2025, include:
- Barbara Bierer, The Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard
- Michael Cuffe, HCA Healthcare
- Esther Krofah, FasterCures, of the Milken Institute
- Virginia Nido, Roche Genentech
“CTTI is honored to welcome this impressive group of leaders from across the clinical trials enterprise to our Executive Committee,” said Sally Okun, CTTI Executive Director. “From medicine to health care to public policy to pharma, these four new EC members will play an important role in helping CTTI achieve our goals to transform clinical trials by 2030.”
“The distinguished and diverse new Executive Committee members will bring a unique combination of expertise, talent and dedication to advance CTTI’s mission,” said CTTI Executive Committee Chair Mark McClellan. “We are looking forward to the valuable perspectives and shared commitment they each bring to our efforts to improve and transform clinical trials.”
The 14-member Executive Committee, chaired by McClellan, and co-chaired by Khair ElZarrad (FDA) and John Alexander (Duke University), includes distinguished U.S. and international thought leaders in government, academia, industry, and patient advocacy who are experienced at envisioning and facilitating improvements in health care and medical research systems. This group ensures that CTTI informs and facilitates meaningful improvements to the design and conduct of clinical trials.
The Executive Committee members whose terms continue are: Donna R. Cryer, Global Liver Institute; Pat Furlong, Parent Project Muscular Dystrophy; Patricia Hurley, American Society of Clinical Oncology; Theodore Lystig, BridgeBio; Robert Temple, FDA; Spiros Vamvakas, European Medicines Agency; and Bram Zuckerman, FDA.
CTTI also wishes to express sincere gratitude to its outgoing Executive Committee members for their 12 years of collective service from 2019-2022: Steven Galson, Amgen; Michael Kolodziej, ADVI Health; Rod MacKenzie, Pfizer; and Pierre Meulien, Innovative Health Initiative.
